Details for Patent: 7,196,205

Which drugs does patent 7,196,205 protect, and when does it expire?

Patent 7,196,205 protects CERDELGA and is included in one NDA.

This patent has thirty-eight patent family members in thirteen countries.

Summary for Patent: 7,196,205

Patent landscape, scope, and claims:

Title:	Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Abstract:	Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
Inventor(s):	Siegel; Craig (Woburn, MA), Shayman; James A. (Ann Arbor, MI), Nelson; Carol A. (Westford, MA), Harris; David J. (Lexington, MA), Copeland; Diane P. (North Billerica, MA)
Assignee:	The Regents of the University of Michigan (Ann Arbor, MI) Genzyme Corporation (Cambridge, MA)
Application Number:	11/091,836
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,196,205
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 7,196,205

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014	AB	RX	Yes	Yes				Y

International Family Members for US Patent 7,196,205

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1409467		C300738	Netherlands
European Patent Office	1409467		CR 2015 00035	Denmark
European Patent Office	1409467		92717	Luxembourg